Lexicon Pharmaceuticals, Inc.
NASDAQ: LXRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael S. Exton
- Employees
- 103
- Headquarters
- The Woodlands, United States
- IPO year
- 2000
- Market cap
- $986.1M
- Website
- https://www.lexpharma.com
Loading LXRX…
Loading profile data…Frequently asked questions about LXRX
What does Lexicon Pharmaceuticals, Inc. (LXRX) do?
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for...
Where does LXRX trade?
Lexicon Pharmaceuticals, Inc. (LXRX) trades on the NASDAQ Global Select.
What sector is LXRX in?
Lexicon Pharmaceuticals, Inc. (LXRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lexicon Pharmaceuticals, Inc.?
Michael S. Exton is the chief executive officer of Lexicon Pharmaceuticals, Inc. (LXRX).
Where is Lexicon Pharmaceuticals, Inc. headquartered?
Lexicon Pharmaceuticals, Inc. is headquartered in United States.
Does LXRX pay a dividend?
Lexicon Pharmaceuticals, Inc. (LXRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LXRX go public?
Lexicon Pharmaceuticals, Inc. (LXRX) completed its initial public offering in 2000.